Beryl Drugs FY 2025-26 Annual Results

Total Revenue: Rs 1931.02 Lakh | Net Profit: Rs 42.48 Lakh

Reader Takeaway: Revenue recovery depends on post-shutdown BFS efficiency; monitor utilization of the increased Rs 8 crore related party transaction limit.

What just happened

Beryl Drugs Ltd filed its 33rd Annual Report for the fiscal year ended March 31, 2026. The company reported a decline in financial metrics, with revenue falling to Rs 19.31 crore from Rs 22.55 crore in the prior year. Net profit also dropped to Rs 42.48 lakh. The board has opted not to declare a dividend, citing the need to conserve cash for expansion projects.

Why this matters

The company’s performance was significantly hindered by a regulatory order from the Food and Drugs Administration, Madhya Pradesh, which halted manufacturing in the Blow Fill Seal (BFS) section from January 2025 to November 2025. With operations now resumed as of December 2025, the company aims to stabilize production volumes.

Related Party Transactions

The company is seeking shareholder approval at the AGM on September 29, 2026, to raise the transaction limit with Aminova Infusions Pvt. Ltd. from Rs 5 crore to Rs 8 crore. Aminova is controlled by Whole-Time Director Shailendra Pathak. The increased limit is intended to support the sale and supply of PP Bottles and FFS products.

Governance Update

The board has regularized the appointment of Mr. Shailendra Pathak as Whole-Time Director and appointed Mrs. Neha Sarda as an Independent Director. Mr. Sudhir Sethi has been re-appointed as a director.

Risks to watch

Investors should note that the statutory auditors flagged non-recognition of professional tax liabilities due to the company's lack of registration. Additionally, the revenue recovery remains contingent on the sustained operational stability of the BFS section following the previously resolved regulatory hurdles.